Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.04 Million USD | -59.35% |
| 2022 | 3.2 Million USD | 33.21% |
| 2021 | 2.4 Million USD | 26.76% |
| 2020 | 1.89 Million USD | 77.91% |
| 2019 | 1.06 Million USD | -11.11% |
| 2018 | 1.2 Million USD | 35.52% |
| 2017 | 886.29 Thousand USD | -15.23% |
| 2016 | 1.04 Million USD | 83.55% |
| 2015 | 569.65 Thousand USD | 74.15% |
| 2014 | 327.1 Thousand USD | -61.96% |
| 2013 | 859.87 Thousand USD | -74.23% |
| 2012 | 3.33 Million USD | 25.0% |
| 2011 | 2.66 Million USD | 479.47% |
| 2010 | 460.72 Thousand USD | -70.04% |
| 2009 | 1.53 Million USD | 1579.66% |
| 2008 | 91.54 Thousand USD | 430.37% |
| 2007 | 17.26 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 680.07 Million USD | 173658.02% |
| 2024 Q2 | 236.22 Thousand USD | -99.94% |
| 2023 Q1 | 444.52 Thousand USD | -38.36% |
| 2023 FY | 1.3 Million USD | -59.35% |
| 2023 Q4 | 391.39 Thousand USD | -99.92% |
| 2023 Q3 | 468.96 Million USD | 83925.87% |
| 2023 Q2 | 558.11 Thousand USD | 25.55% |
| 2022 Q1 | 595.65 Thousand USD | -37.11% |
| 2022 Q4 | 721.2 Thousand USD | -8.12% |
| 2022 Q2 | 1.1 Million USD | 85.58% |
| 2022 Q3 | 784.97 Thousand USD | -28.99% |
| 2022 FY | 3.2 Million USD | 33.21% |
| 2021 Q4 | 947.2 Thousand USD | 26.82% |
| 2021 Q1 | 270.9 Thousand USD | -53.15% |
| 2021 Q2 | 442.78 Thousand USD | 63.45% |
| 2021 Q3 | 746.86 Thousand USD | 68.67% |
| 2021 FY | 2.4 Million USD | 26.76% |
| 2020 FY | 1.89 Million USD | 77.91% |
| 2020 Q1 | 138.4 Thousand USD | -37.37% |
| 2020 Q2 | 683.7 Thousand USD | 394.01% |
| 2020 Q3 | 499.03 Thousand USD | -27.01% |
| 2020 Q4 | 578.27 Thousand USD | 15.88% |
| 2019 Q3 | 209.62 Thousand USD | 3.71% |
| 2019 Q2 | 202.12 Thousand USD | -53.52% |
| 2019 Q1 | 434.9 Thousand USD | -14.27% |
| 2019 Q4 | 220.98 Thousand USD | 5.42% |
| 2019 FY | 1.06 Million USD | -11.11% |
| 2018 Q3 | 259.33 Thousand USD | 10.26% |
| 2018 FY | 1.2 Million USD | 35.52% |
| 2018 Q1 | 199.32 Thousand USD | -22.68% |
| 2018 Q2 | 235.2 Thousand USD | 18.0% |
| 2018 Q4 | 507.27 Thousand USD | 95.6% |
| 2017 FY | 886.29 Thousand USD | -15.23% |
| 2017 Q4 | 257.77 Thousand USD | 23.84% |
| 2017 Q3 | 208.15 Thousand USD | -13.36% |
| 2017 Q2 | 240.24 Thousand USD | 33.38% |
| 2017 Q1 | 180.11 Thousand USD | -50.26% |
| 2016 Q4 | 362.15 Thousand USD | 100.85% |
| 2016 Q1 | 226.04 Thousand USD | 11.5% |
| 2016 Q3 | 180.3 Thousand USD | -34.92% |
| 2016 FY | 1.04 Million USD | 83.55% |
| 2016 Q2 | 277.06 Thousand USD | 22.57% |
| 2015 Q3 | 178.65 Thousand USD | 57.29% |
| 2015 Q4 | 202.73 Thousand USD | 13.48% |
| 2015 FY | 569.65 Thousand USD | 74.15% |
| 2015 Q1 | 74.87 Thousand USD | 394.47% |
| 2015 Q2 | 113.58 Thousand USD | 51.69% |
| 2014 FY | 327.1 Thousand USD | -61.96% |
| 2014 Q1 | 122.88 Thousand USD | 9.92% |
| 2014 Q4 | 15.14 Thousand USD | -76.41% |
| 2014 Q3 | 64.18 Thousand USD | -49.64% |
| 2014 Q2 | 127.46 Thousand USD | 3.73% |
| 2013 Q2 | 311.37 Thousand USD | 14.05% |
| 2013 FY | 859.87 Thousand USD | -74.23% |
| 2013 Q4 | 111.79 Thousand USD | -31.71% |
| 2013 Q1 | 273 Thousand USD | -66.69% |
| 2013 Q3 | 163.71 Thousand USD | -47.42% |
| 2012 Q1 | 983.27 Thousand USD | -10.13% |
| 2012 Q4 | 819.63 Thousand USD | 40.45% |
| 2012 Q3 | 583.58 Thousand USD | -38.62% |
| 2012 FY | 3.33 Million USD | 25.0% |
| 2012 Q2 | 950.77 Thousand USD | -3.3% |
| 2011 Q3 | 946.99 Thousand USD | 53.14% |
| 2011 Q4 | 1.09 Million USD | 15.54% |
| 2011 FY | 2.66 Million USD | 479.47% |
| 2011 Q1 | 10.22 Thousand USD | 233.51% |
| 2011 Q2 | 618.38 Thousand USD | 5949.5% |
| 2010 Q2 | 96.77 Thousand USD | -64.98% |
| 2010 Q4 | 3065.00 USD | -96.37% |
| 2010 Q3 | 84.52 Thousand USD | -12.65% |
| 2010 Q1 | 276.35 Thousand USD | -36.92% |
| 2010 FY | 460.72 Thousand USD | -70.04% |
| 2009 Q2 | 433.42 Thousand USD | 55.59% |
| 2009 FY | 1.53 Million USD | 1579.66% |
| 2009 Q3 | 393.28 Thousand USD | -9.26% |
| 2009 Q4 | 438.12 Thousand USD | 11.4% |
| 2009 Q1 | 278.57 Thousand USD | 61259.25% |
| 2008 Q2 | 44.94 Thousand USD | -18.24% |
| 2008 FY | 91.54 Thousand USD | 430.37% |
| 2008 Q3 | 5000.00 USD | -88.88% |
| 2008 Q4 | 454.00 USD | -90.92% |
| 2008 Q1 | 54.97 Thousand USD | 466.12% |
| 2007 Q3 | 7550.00 USD | 0.0% |
| 2007 FY | 17.26 Thousand USD | 0.0% |
| 2007 Q4 | 9711.00 USD | 28.62% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -53.412% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 59.368% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 93.068% |
| Nascent Biotech, Inc. | 2.22 Million USD | 8.125% |
| Rebus Holdings, Inc. | 664 Thousand USD | -208.54% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 94.501% |
| Qrons Inc. | 643.67 Thousand USD | -218.282% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -425.894% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.433% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -393.095% |
| Skye Bioscience, Inc. | 13.54 Million USD | 84.878% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.639% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 58.342% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -682.767% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.607% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 29.748% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -36.408% |
| Mesoblast Limited | 5.9 Million USD | 65.288% |
| Marizyme, Inc. | 19.23 Million USD | 89.352% |
| Genus plc | 147.7 Million USD | 98.613% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 76.664% |
| Pharming Group N.V. | 225.49 Million USD | 99.091% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -52.712% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 75.432% |
| ContraFect Corporation | 56.88 Million USD | 96.399% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 53.53% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -38.543% |
| IMV Inc. | 37.7 Million USD | 94.567% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 26.579% |
| MultiCell Technologies, Inc. | 567.42 USD | -360956.184% |
| ONE Bio Corp. | 6.44 Million USD | 68.207% |
| Accustem Sciences Inc. | 3.74 Million USD | 45.316% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.616% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -285.122% |
| Q BioMed Inc. | 3.43 Million USD | 40.386% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 91.711% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 22.029% |
| Biomind Labs Inc. | 994.18 Thousand USD | -106.069% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.937% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -16.425% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 69.504% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -9.887% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 8294.82% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 87.204% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -11.64% |
| GB Sciences, Inc. | 1.42 Million USD | -44.223% |
| Alpha Cognition Inc. | 9.7 Million USD | 78.892% |
| HST Global, Inc. | 140.9 Thousand USD | -1353.941% |
| CSL Limited | 3.44 Billion USD | 99.941% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -82.122% |
| Halberd Corporation | 74.84 Thousand USD | -2637.373% |
| Enzolytics Inc. | 2.17 Million USD | 6.001% |
| Agentix Corp. | 1.37 Million USD | -49.349% |
| Resverlogix Corp. | 12.71 Million USD | 83.884% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 43.882% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.866% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -96.236% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 14.812% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -29.718% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 39.832% |
| AVAX Technologies, Inc. | 7.31 Million USD | 71.975% |
| Zenith Capital Corp. | 8.94 Million USD | 77.092% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.752% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -11659.974% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 16.56% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1094.517% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -6.653% |
| Kadimastem Ltd | 2.41 Million USD | 14.995% |
| Helix BioMedix, Inc. | 1.97 Million USD | -3.888% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 81.147% |
| BioStem Technologies, Inc. | 22.97 Million USD | 91.083% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1028.856% |
| LadRx Corporation | 3.81 Million USD | 46.253% |
| Cell Source, Inc. | 4.32 Million USD | 52.635% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -121.839% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -121.839% |
| NovAccess Global Inc. | 2.46 Million USD | 16.948% |
| Affymax, Inc. | 39.38 Million USD | 94.798% |
| Itoco Inc. | 919.14 Thousand USD | -122.893% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 51.663% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -83.084% |
| Mobile Lads Corp. | 554.54 Thousand USD | -269.438% |
| CytoDyn Inc. | 18.05 Million USD | 88.655% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -8039.795% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -830.899% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -44.296% |
| SYBLEU INC | 160.87 Thousand USD | -1173.468% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -12.794% |
| International Stem Cell Corporation | 5.27 Million USD | 61.133% |
| Bioxytran, Inc. | 3.82 Million USD | 46.371% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3791.769% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -9970.811% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 94.351% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -26.62% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -178.419% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 34.146% |
| Neutra Corp. | 243.82 Thousand USD | -740.25% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 88.264% |
| PureTech Health plc | 144.59 Million USD | 98.583% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 90.001% |
| IXICO plc | 4.7 Million USD | 56.475% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 76.711% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.26% |
| CSL Limited | 3.89 Billion USD | 99.947% |
| Cellectis S.A. | 97.32 Million USD | 97.895% |